Stay updated on LGX818/MEK162 vs Vemurafenib/LGX818 in Melanoma Clinical Trial
Sign up to get notified when there's something new on the LGX818/MEK162 vs Vemurafenib/LGX818 in Melanoma Clinical Trial page.

Latest updates to the LGX818/MEK162 vs Vemurafenib/LGX818 in Melanoma Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
- Check35 days agoNo Change Detected
- Check42 days agoChange DetectedThe page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference6%
- Check49 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.3%
- Check64 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.3%
- Check71 days agoChange DetectedThe website has updated the 'type of intervention' feature from version 2.13.3 to 2.14.0, indicating a significant change in this functionality.SummaryDifference1.0%
- Check93 days agoChange DetectedA new addition was made on December 20, 2024, while a deletion occurred on November 5, 2024.SummaryDifference0.7%
Stay in the know with updates to LGX818/MEK162 vs Vemurafenib/LGX818 in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the LGX818/MEK162 vs Vemurafenib/LGX818 in Melanoma Clinical Trial page.